DDR

News alerts, weekly reports and conference planners

DDR	Prostate Cancer	DDR	Prostate Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
DDR	Cervical Cancer	DDR	Cervical Cancer	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
DDR	Cholangiocarcinoma	DDR	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Triple Negative Breast Cancer	DDR	Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	abiraterone acetate + prednisone Resistant: C3 – Early Trials abiraterone acetate + prednisone Resistant : C3	abiraterone acetate + prednisone Resistant: C3 – Early Trials abiraterone acetate + prednisone Resistant : C3
DDR	Pancreatic Ductal Adenocarcinoma	DDR	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3
DDR	Renal Cell Carcinoma	DDR	Renal Cell Carcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
DDR	Breast Cancer	DDR	Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Bladder Cancer	DDR	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Melanoma	DDR	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
DDR	Pancreatic Cancer	DDR	Pancreatic Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
DDR	Hepatocellular Cancer	DDR	Hepatocellular Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
DDR	Soft Tissue Sarcoma	DDR	Soft Tissue Sarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
DDR	Solid Tumor	DDR	Solid Tumor	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
DDR	Ovarian Cancer	DDR	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
DDR	Clear Cell Renal Cell Carcinoma	DDR	Clear Cell Renal Cell Carcinoma	VEGFR inhibitor Sensitive: C3 – Early Trials VEGFR inhibitor Sensitive : C3	VEGFR inhibitor Sensitive: C3 – Early Trials VEGFR inhibitor Sensitive : C3
DDR	Breast Cancer	DDR	Breast Cancer	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Urothelial Cancer	DDR	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
DDR	Solid Tumor	DDR	Solid Tumor	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
DDR	Triple Negative Breast Cancer	DDR	Triple Negative Breast Cancer	AZD1390 Sensitive: D – Preclinical AZD1390 Sensitive : D	AZD1390 Sensitive: D – Preclinical AZD1390 Sensitive : D

DDR

Associations